After the pharma industry took a loss with the passage of the Inflation Reduction Act, companies are scouring for ways to blunt the new law’s effects. As the incoming chair of the powerful trade group PhRMA, Novartis CEO Vas Narasimhan has ideas about how the industry should respond.
Data has shown that treatment with Kesimpta is associated with fewer relapses and reduced risk of worsening disability
Novartis has announced new long-term data from the phase 3 Asclepios trials into Kesimpta (ofatumumab) for patients with relapsing multiple sclerosis (RMS), following up to four years of treatment.
Multiple sclerosis is a chronic inflammatory disease of the central nervous system, characterised by myelin destruction and axonal damage in the brain, optic nerves and spinal cord. It affects approximately 2.3 million people worldwide.
